World Journal of *Clinical Cases*

Thrice Monthly Volume 13 Number 7 March 6, 2025





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

Contents

Thrice Monthly Volume 13 Number 7 March 6, 2025

EDITORIAL

de Carvalho JF, Lerner A, Benzvi C. Foot reflexology in autoimmune diseases: Effectiveness and mechanisms. World J Clin Cases 2025; 13(7): 97403 [DOI: 10.12998/wjcc.v13.i7.97403]

Roganovic J. Late effects of the treatment of childhood cancer. World J Clin Cases 2025; 13(7): 98000 [DOI: 10.12998/ wjcc.v13.i7.98000

Wu X, Min XH, Xu HF, Ud Din MJ, Zhang G. Intersection of two rare conditions: Clinical reflection on tuberous sclerosis combined with primary lymphedema. World J Clin Cases 2025; 13(7): 99903 [DOI: 10.12998/wjcc.v13.i7. 99903

Lucke-Wold B, Karamian A. Effect of esketamine on reducing postpartum pain and depression. World J Clin Cases 2025; 13(7): 100422 [DOI: 10.12998/wjcc.v13.i7.100422]

ORIGINAL ARTICLE

Retrospective Study

Kaw P, Behari A, Sharma S, Kumar A, Singh RK. Internal hernia as a rare cause of small bowel obstruction: An insight from 13 years of experience. World [Clin Cases 2025; 13(7): 92254 [DOI: 10.12998/wjcc.v13.i7.92254]

Shi MQ, Chen J, Ji FH, Zhou H, Peng K, Wang J, Fan CL, Wang X, Wang Y. Prognostic impact of hypernatremia for septic shock patients in the intensive care unit. World J Clin Cases 2025; 13(7): 95430 [DOI: 10.12998/wjcc.v13.i7. 95430]

SYSTEMATIC REVIEWS

Javid K, Akins X, Lemaster NG, Ahmad A, Stone AV. Impact of time between meniscal injury and isolated meniscus repair on post-operative outcomes: A systematic review. World J Clin Cases 2025; 13(7): 95004 [DOI: 10. 12998/wjcc.v13.i7.95004

CASE REPORT

Wang YL, Li J. Insulin-induced severe thyrotoxic periodic paralysis: A case report. World J Clin Cases 2025; 13(7): 101214 [DOI: 10.12998/wjcc.v13.i7.101214]

Tsang HY, Yong CC, Wang HP. Mesenteric ischemia with intrasplenic gas: A case report. World J Clin Cases 2025; 13(7): 101901 [DOI: 10.12998/wjcc.v13.i7.101901]

LETTER TO THE EDITOR

Zhang L, Huang PJ, Deng X, Tang J, Zhai Y, Wang T. Physical rehabilitation for sensorineural hearing loss in childhood: Progress and challenges. World J Clin Cases 2025; 13(7): 97847 [DOI: 10.12998/wjcc.v13.i7.97847]



Contents

Thrice Monthly Volume 13 Number 7 March 6, 2025

ABOUT COVER

Peer Reviewer of World Journal of Clinical Cases, Serghei Covantsev, MD, Surgeon, Department of Clinical Research and Development, Botkin Hospital, Moscow 125284, Russia. kovantsev.s.d@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJCC as 1.0; JIF without journal self cites: 0.9; 5-year JIF: 1.1; JIF Rank: 170/329 in medicine, general and internal; JIF Quartile: Q3; and 5-year JIF Quartile: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang, Production Department Director: Xiang Li, Cover Editor: Jin-Lei Wang.

NAME OF JOURNAL World Journal of Clinical Cases	INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2307-8960 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
April 16, 2013	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Thrice Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
March 6, 2025	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2025 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



W J C C World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2025 March 6; 13(7): 95430

DOI: 10.12998/wjcc.v13.i7.95430

ISSN 2307-8960 (online)

ORIGINAL ARTICLE

Retrospective Study Prognostic impact of hypernatremia for septic shock patients in the intensive care unit

Mai-Qing Shi, Jun Chen, Fu-Hai Ji, Hao Zhou, Ke Peng, Jun Wang, Chun-Lei Fan, Xu Wang, Yang Wang

Specialty type: Medicine, research and experimental

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade B Novelty: Grade C Creativity or Innovation: Grade C Scientific Significance: Grade B

P-Reviewer: Ghanbari M

Received: April 10, 2024 Revised: October 4, 2024 Accepted: November 13, 2024 Published online: March 6, 2025 Processing time: 229 Days and 1.6 Hours



Mai-Qing Shi, Jun Chen, Fu-Hai Ji, Ke Peng, Chun-Lei Fan, Xu Wang, Yang Wang, Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China

Hao Zhou, Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China

Jun Wang, Intensive Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China

Co-first authors: Mai-Qing Shi and Jun Chen.

Co-corresponding authors: Xu Wang and Yang Wang.

Corresponding author: Yang Wang, Doctor, Department of Anesthesiology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215006, Jiangsu Province, China. sdfyyzxicu@sina.com

Abstract

BACKGROUND

Hypernatremia represents a significant electrolyte imbalance associated with numerous adverse outcomes, particularly in cases of intensive care unit (ICU)acquired hypernatremia (IAH). Nevertheless, its relevance in patients with septic shock remains uncertain.

AIM

To identify independent risk factors and their predictive efficacy for IAH to improve outcomes in patients with septic shock.

METHODS

In the present retrospective single-center study, a cohort of 157 septic shock patients with concurrent hypernatremia in the ICU at The First Affiliated Hospital of Soochow University, between August 1, 2018, and May 31, 2023, were analyzed. Patients were categorized based on the timing of hypernatremia occurrence into the IAH group (n = 62), the non-IAH group (n = 41), and the normonatremia group (n = 54).

RESULTS

In the present study, there was a significant association between the high serum



sodium concentrations, excessive persistent inflammation, immunosuppression and catabolism syndrome and chronic critical illness, while rapid recovery had an apparent association with normonatremia. Moreover, multivariable analyses revealed the following independent risk factors for IAH: Total urinary output over the preceding three days [odds ratio (OR) = 1.09; 95%CI: 1.02–1.17; P = 0.014], enteral nutrition (EN) sodium content of 500 mg (OR = 2.93; 95%CI: 1.13–7.60; P = 0.027), and EN sodium content of 670 mg (OR = 6.19; 95%CI: 1.75–21.98; P = 0.005) were positively correlated with the development of IAH. Notably, the area under the curve for total urinary output over the preceding three days was 0.800 (95%CI: 0.678–0.922, P = 0.001). Furthermore, maximum serum sodium levels, the duration of hypernatremia, and varying sodium correction rates were significantly associated with 28-day in-hospital mortality in septic shock patients (P < 0.05).

CONCLUSION

The present findings illustrate that elevated serum sodium level was significantly associated with a poor prognosis in septic shock patients in the ICU. It is highly recommended that hypernatremia be considered a potentially important prognostic indicator for the outcome of septic shock.

Key Words: Hypernatremia; Hypernatremia acquired in the intensive care unit; Septic shock; Persistent inflammation; Immunosuppression; Catabolism syndrome; Chronic critical illness; Prognosis

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The aim of the present observational study was to improve outcomes in patients with septic shock by identifying independent risk factors and their predictive efficacy for intensive care unit-acquired hypernatremia. Additionally, the present findings indicate a significant association between the prognosis of septic shock patients and variables such as peak serum sodium levels, duration of hypernatremia, and differing rates of sodium correction. As such, the present authors propose that hypernatremia may serve as a critical predictive marker for the prognosis of septic shock.

Citation: Shi MQ, Chen J, Ji FH, Zhou H, Peng K, Wang J, Fan CL, Wang X, Wang Y. Prognostic impact of hypernatremia for septic shock patients in the intensive care unit. *World J Clin Cases* 2025; 13(7): 95430 URL: https://www.wjgnet.com/2307-8960/full/v13/i7/95430.htm DOI: https://dx.doi.org/10.12998/wjcc.v13.i7.95430

INTRODUCTION

Sepsis is defined as an inflammatory body response to infection, with severe sepsis and septic shock being more severe forms[1]. Globally, the incidence of sepsis is estimated at 48.9 million cases, with 11 million sepsis-related deaths reported, accounting for 19.7% of all deaths worldwide[2]. Septic shock, in particular, is associated with significantly higher 30- and 90-day mortality rates, both exceeding 30%[3]. Septic shock has a significant negative impact on health outcomes in intensive care unit (ICU) patients, facing three clinical outcomes in addition to high costs and longer hospital stays: (1) Early death within 14 days; (2) Rapid recovery (RR); and (3) Chronic critical illness (CCI)[4]. Previous research has demonstrated that patients with CCI often develop persistent inflammation, immunosuppression, and catabolism syndrome (PICS), which contributes to the poor clinical outcomes observed in this group[5,6]. Specifically, following the activation of both pro-inflammatory and anti-inflammatory responses, survivors either experience RR or progress into a state of persistent catabolism and organ dysfunction, leading to CCI. Unfortunately, approximately one-third of survivors develop CCI, characterized by a poor quality of life and infrequent recovery[7].

Hypernatremia (serum sodium concentration > 145 mmol/L) is a common electrolyte disturbance[8]. Approximately 7% of patients presented with hypernatremia upon admission, and this prevalence increased to as much as 9% during their ICU stay, with 77.1% of critically ill patients with sepsis being affected[9,10]. Notably, compared to non ICU-acquired hypernatremia (IAH), IAH is associated with increased morbidity and mortality[11,12]. In septic shock, chronic catabolism driven by inflammation can lead to the development of hypernatremia[13]. Conversely, hypernatremia can exacerbate protein catabolism and systemic inflammation, contributing to the progression of PICS[14]. Thus, intense inflammation can lead to an increase in serum sodium concentration, while elevated serum sodium levels may also act as a significant promoter of the inflammatory response. Recently, questions have been raised regarding whether serum sodium levels directly influence the severity and prognosis of patients with septic shock[13]. In response, the specific relationship between hypernatremia and clinical trajectories of septic shock patients has become a primary focus both domestically and internationally. In order to improve the clinical prognosis of septic shock patients, it is also particularly important to identify the independent risk factors with high predictive value for hypernatremia.

As a result, a single-center retrospective study was conducted to analyze the correlation between hypernatremia and PICS, as well as its association with clinical outcomes such as CCI and RR. Furthermore, independent risk factors for IAH were identified, and their predictive efficacy was evaluated to improve the prognosis of septic shock patients. Finally, the

Raishideng® WJCC | https://www.wjgnet.com

relationship between serum sodium levels and the prognosis of septic shock patients was examined by analyzing the correlation between IAH and non-IAH, the duration of hypernatremia, blood sodium levels, sodium correction rates, and 28-day in-hospital mortality.

MATERIALS AND METHODS

Setting and participants

The present single-center retrospective study included adult patients with septic shock admitted to the ICU at The First Affiliated Hospital of Soochow University between August 1, 2018, and May 31, 2023. The inclusion criteria for the study were: (1) Adults aged ≥ 18 years; (2) Serum sodium concentration greater than 135 mmol/L during or prior to ICU admission; and (3) A diagnosis of septic shock. Exclusion criteria were: (1) Patients with missing serum sodium concentration data; (2) Patients with brain death; (3) Patients with a high likelihood of death within 48 hours; (4) Patients with hyponatremia; and (5) Pregnant patients. The patient screening flowchart is presented in Figure 1.

Variables and outcomes data

Data were collected from patients' medical records, encompassing various parameters. Demographic data included age and gender. Comorbidities recorded included hypertension, diabetes mellitus, coronary heart disease, cerebral infarction, and sepsis-associated encephalopathy (SAE). Laboratory parameters collected included albumin, C-reactive protein (CRP), the serum urea to serum creatinine ratio (BUN/SCr), serum prealbumin, myoglobin (Myo), and maximum body temperature, among others. Interventions such as mechanical ventilation and continuous renal replacement therapy (CRRT) were also noted. Clinical scores recorded included the Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II (APACHE II), quick Sequential Organ Failure Assessment (qSOFA), and SOFA. Additionally, information on pathogenic bacteria, including Gram-positive (G+), Gram-negative (G-) bacteria, and fungi, was documented. The primary clinical outcomes included length of stay (LOS) in the ICU, LOS outside the ICU, early death within 14 days and 28-day in-hospital mortality.

Main definition

CCI was defined for patients with an ICU stay of \geq 14 days, accompanied by evidence of persistent organ dysfunction, as determined by components of the SOFA score[15]. RR patients were defined as those who were discharged from the ICU within 14 days with complete resolution of organ dysfunction[14]. PICS was defined by the presence of specific laboratory markers suggested in the literature. These included an ICU stay of at least 10 days, evidence of inflammation (CRP > 50 mg/L for \geq 2 days), immunosuppression (lymphocyte count < 0.8 × 10⁹/L for \geq 2 days), and catabolism (weight loss > 10%, body mass index < 18, or albumin < 30 g/L during hospitalization)[16]. An overview of other definitions used in the present study is given in Supplementary Table 1.

Statistical analysis

Categorical variables were presented as percentages of the total number of cases and compared using the Pearson χ^2 test or Fisher's Exact test. Quantitative variables with a normal distribution were expressed as mean ± SD, with differences evaluated using one-way analysis of variance. Continuous variables with a non-normal distribution were analyzed using the Kruskal-Wallis test and reported as median and interquartile range. Univariate logistic regression analysis was performed to identify risk factors for IAH, and variables found to be significant were further analyzed using multivariate logistic regression. Receiver-operating characteristic (ROC) curves were plotted, and the area under the curve (AUC) was calculated to assess the predictive value of independent risk factors for IAH. Kaplan-Meier analysis was used to assess the impact of IAH, maximum serum sodium levels, duration of hypernatremia, and sodium correction rate on 28-day inhospital mortality. A P value of < 0.05 was considered statistically significant. Statistical analyses were conducted using SPSS version 25.0, with ROC and Kaplan-Meier analyses performed using GraphPad Prism version 8.0.2.

RESULTS

Characteristics of patients

Among the 9345 patients admitted to the ICU, 157 patients fulfilled the inclusion criteria. The baseline characteristics of patients are shown in Table 1. Patients were divided into three groups: IAH (n = 62, 39.49%), non-IAH (n = 41, 26.11%), and normonatremia (n = 54, 34.39%). The mean age of all 157 patients was 65.85 ± 15.64 years old, and 31.85% of patients were female.

As shown in Table 1, the indicators of significant differences were as follows: SAE (P = 0.002), the concentration of Cl⁻ (P = 0.019), BUN/SCr (p = 0.001), serum prealbumin (P = 0.042), Myo (P = 0.008), maximum body temperature (P = 0.017), need for mechanical ventilation (MV, P = 0.002), APACHE II score (P = 0.001), infection with G⁻ bacteria (P = 0.003) and ICU-LOS (*P* < 0.001).

Association between hypernatremia and PICS, CCI and RR

As shown in Figure 2, only 16.28% of PICS patients had normal sodium levels, similar to those in CCI groups (15.00%).



Shi MQ et al. Hypernatremia in patients with septic shock

(n = 62)(n = 64)(n = 54)App. years66.30 ± 13.4066.10 ± 10.406.30 ± 13.100.205App. years26.68 a)10 (24.39)18 (3.33)0.476Comorbidites114 (6.0024 (44.400.30Dables endities16 (25.31)21 (24.9)10 (RS2)0.11Chenden infraritom16 (6.5)0.124.100.2620.262Cardend infraritom0.104.510.124.0113.60.010.262Cardend infraritom10.92 ± 0.2212.80.3113.70.070.97Cardend infraritom10.92 ± 0.2210.80.21.2010.91.04.1320.97Cardend infraritom10.82 ± 0.82.10.2010.03.06.63.10.400.99Car, mand/L10.82 ± 0.82.01.2010.03.06.63.10.400.91Car, mand/L18.80.91.30.2116.80.21.82.5110.03.06.64.10.400.92Car, mand/L18.80.91.30.2116.80.21.82.5110.03.06.64.10.400.92DUN/SCr16.80.21.82.5110.93.04.64.13.210.920.92Car, mand/L18.90.11.52.52.5110.921.921.92DUN/SCr16.92.05.10.0110.50.02.02.97.310.921.92Car, marg/L18.90.11.52.52.1010.911.921.92PUT_MC/L18.90.11.52.52.1010.921.921.92Car, mand/L18.90.11.52.5210.911.921.92PUT_MC/L18.90.11.52.5210.911.921.92PUT_MC/L18.90.11.52.5210.921.921.92<	Table 1 Baseline clinical characteristics, <i>n</i> (%)/mean ± SD/median (25 th -75 th percentiles)				
(n=62)(n=74)(n=74)Ago, yoars6430 15.06430 15.00.850Ago, yoars6430 15.06430 15.00.476See, Fenalo2.65.4%10.437016.33.00.476Conorbibilies119.00010.65.1010.63.00.50Diabetes mainine16.25.100.145.010.65.100.660.66Corbeat infarction10.61.210.145.010.84.00.660.66Carbeat infarction10.61.210.145.010.84.00.660.66Carbeat infarction10.61.210.85.0.210.100.00.670.66Carbeat infarction10.81.0.1.170.81.0.2.1010.90.66.1.0.00.89Carbeat infarction10.80.0.1.2010.20.0.85.1.00.1010.90.66.1.0.00.89Carbeat infarction10.80.0.1.2010.20.0.85.1.00.1010.90.66.1.00.00.90Carbeat infarction10.80.0.2.1.2010.90.0.6.1.0.00.900.90Carbeat infarction10.80.0.2.1.2010.90.0.6.1.0.00.900.90Carbeat infarction10.80.0.2.1.2010.90.0.0.00.900.90Carbeat infarction10.80.0.2.1.2010.90.0.0.00.900.90Carbeat infarction10.80.0.2.1.2010.90.0.0.00.900.90Carbeat infarction10.90.0.0.0.010.90.0.0.0.00.900.90Carbeat infarction10.90.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	Variable	IAH	Non-IAH	Normonatremia	Duralua
Barbon SeriemalonJordenJordenJordenJordenConorbidius11		(<i>n</i> = 62)	(<i>n</i> = 41)	(<i>n</i> = 54)	P value
ConstitutionNon-stateSector StateSector StateSector StateHyperhexionS100000S100000S100000S100000S100000Dabetes mellinesGESS1000S1205000S1635000S1600000Carbeal inflactionJ0231000J0231000J04070000S10000000Carbeal inflactionJ0231000J02010000J020100000J020100000Carbeal inflactionJ0231000J020100000J020100000J0201000000Carbeal inflactionJ020100000J020100000J0201000000J0201000000Carbeal inflactionJ0201000000J0201000000J0201000000J0201000000Carbeal inflactionJ02010000000J0201000000J02010000000J02010000000Carbeal inflactionJ02010000000J02010000000J020100000000J02010000000000000000000000000000000000	Age, years	66.20 ± 15.40	66.10 ± 16.90	65.30 ± 15.10	0.956
Hyperbasion16,000,00020,000,00020,000,00020,000,00020,000,000Diabetsmellines6,000,000,0006,000,000,0006,000,0006,000,000Cordend inforted10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,000,000,00010,000,00010,000,000Carbon10,000,00010,000,000,00010,000,00010,000,000Carbon10,000,00010,000,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,00010,000,000Carbon10,000,00010,000,00010,000,000 <td>Sex (Female)</td> <td>22 (35.48)</td> <td>10 (24.39)</td> <td>18 (33.33)</td> <td>0.476</td>	Sex (Female)	22 (35.48)	10 (24.39)	18 (33.33)	0.476
NumberPart of the set of the s	Comorbidities				
CHDAct AACAACAACAACACarebra infarction10 (b13)614.63)3 6.59)0.02SAU20 (02.2)2 (08.54)13 (24.07)0.02Laboratory parameters3.94 10.023.92 10.031.02 (0.06, 11.2)0.02Ca ²⁺ , manol/L1.08 0.10, 1.101.08 (10.2, 1.00)1.03 (0.06, 51, 40.6)0.03Ca ²⁺ , manol/L1.08.50 (0.03, 21.20)1.030 (06.65, 104.03)0.010.01SC4, manol/L1.08.50 (0.10, 21.20)1.030 (06.65, 104.03)0.01SC4, manol/L1.08.50 (0.10, 21.20)1.050 (0.14.3, 24.14)0.02SC4, manol/L1.8.00 (1.15, 25.80)2.051 (0.11.8), 24.14)0.02SC7, manol/L1.26.24 0.50.009.751 (3.3, 1.6.0)1.506 (1.4.3, 24.14)0.02SC7, manol/L1.26.24 0.50.009.751 (3.3, 1.6.0)1.506 (1.4.3, 24.14)0.02SC7, manol/L1.26.24 0.50.009.751 (3.3, 1.6.0)1.506 (3.0, 1.5.00)0.02SC7, manol/L1.26.24 0.50.009.751 (3.3, 1.6.0)1.562 (3.4.0.0)0.02SC7, manol/L1.26.24 0.50.009.751 (3.5, 1.6.0)1.562 (3.4.0.0)0.02SC7, manol/L1.26.24 0.50.009.751 (3.5, 1.6.0)1.562 (3.4.0.0)0.02SC7, manol/L1.26.24 0.50.001.562 (3.4.0.0)0.562 (3.4.0.0)0.562SC7, manol/L1.26.24 0.50.001.562 (3.4.0.0)0.5620.562SC7, manol/L1.26.24 0.50.001.562 (3.5.0.0)1.562 (3.5.0.0)0.562SC7, manol/L	Hypertension	31 (50.00)	23 (56.10)	24 (44.44)	0.530
Ceeden link10(13)10(43)10(5)10(5)10(5)SAF0(23)0(23)0(23)0(23)0(23)Labotaty3910(23)0(21)0(21)0(21)0(21)Ca ²¹ , man(J.0(20,000)0(20,000)0(20,000)0(20,000)0(20,000)Ca ²¹ , man(J.0(20,000)0(20,000)0(20,000)0(20,000)0(20,000)0(20,000)Cy, man(J.0(20,000)	Diabetes mellitus	16 (25.81)	9 (21.95)	10 (18.52)	0.611
SAEQ. Q. Q. Q. Q. S. J.Q. Q. Q	CHD	4 (6.45)	1(2.44)	4 (7.41)	0.626
Laboratory parameters Laboratory parameters Laboratory parameters K*, mmol/L 3.89 ± 0.62 3.92 ± 0.83 4.17 ± 0.74 0.078 G* ² , mmol/L 1.08 (1.04, 1.17) 1.08 (1.02, 1.20) 1.09 (1.06, 1.12) 0.895 Cr, mmol/L 1.02 \$5 (98.03, 106.03) 103.09 (98.50, 112.05) 103.09 (96.5, 114.03) 0.01 SCr, mmol/L 1.48 \$0 (1.03, 214.75) 105.09 (1.03, 27, 202.25) 0.01 SUN, MORAL 2.623 (49.83, 204.87) 2.755 ± 3.71 2.752 ± 5.40 0.94 SUN, MORAL 1.20 (40, 50.00) 9.75 (1.13, 31.61) 1.21 (3.63, 118.38) 0.94 SURD, PolyL 1.22 (40, 50.00) 1.247 (1.43, 41.40) 0.94 0.94 SUN, PolyL 1.29 (40, 50.00) 1.454 (2.43, 118.38) 0.94 0.94 SURD, PolyL 1.92 (40, 50.00 1.94 (9.21, 0.25) 0.94 (0.21, 0.63) 0.94 SUN, PolyL 1.92 (40, 50.00 1.94 (9.21, 0.25) 0.94 (0.21, 0.25) 0.96 SURD, PolyL 1.94 (9.20, 0.20) 0.24 (9.21, 0.25) 0.97 0.97 SUN, PolyL 1.94	Cerebral infarction	10 (16.13)	6 (14.63)	3 (5.56)	0.186
N mainS89 0.62S92 0.834.72 0/40.078Ga ² , mmol/L1.86 (0.4.1.7)1.86 (0.2.1.20)109 (0.6.1.12)0.85Gr, mmol/L10285 (80.3.0.6.00)103.0.968.3.0.12.0.05103.0.966.3.0.40.00)0.01SCr, µmol/L1.88 (0.13.2.1.20)1.355 (72.0.297.38)0.01SUN/SC2.623 (49.8.9.24.87)2.556 (49.1.8.71.69)15.66 (13.3.7.2.52.0.27)0.01BUN, mol/L1.890 (11.1.5.25.80)2.551 (13.0.2.9.25.51)15.06 (13.3.7.2.52.0.2)0.01SC, µmol/L1.890 (11.1.5.25.80)2.551 (13.0.2.9.25.51)15.06 (13.3.7.2.52.0.2)0.01BUN, mol/L1.890 (11.5.25.80)2.551 (13.0.2.9.25.51)15.06 (13.3.7.2.50.25.00)0.02SC, µmol/L1.890 (11.5.25.80)2.551 (13.0.2.9.25.51)15.06 (13.3.7.2.50.25.00)0.02SC, µmol/L1.890 (11.5.25.80)2.575 (13.7.1.6.2)15.02 (0.3.1.6.1.8.3.9.0)0.02SC, µmol/L1.890 (13.2.9.25.00)2.575 (13.7.1.6.2)15.62 (13.6.1.8.3.9.0)0.62SC, µmol/L1.92 (40.5.00)4.97 (13.6.1.8.3.9.0)0.6215.62SC, µmol/L1.92 (14.2.1.2.1.2)2.560 (13.6.1.8.3.9.0)0.62SC, µmol/L1.92 (40.5.9.0)1.92 (14.2.1.2.1.2)1.92 (14.2.1.2.1.2)SC, µmol/L1.92 (40.5.9.0)1.92 (12.0.2.1.6.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2	SAE	20 (32.23)	24 (58.54)	13 (24.07)	0.002
Arrower Arrower (T, amal/L18(1.0.1.17)1.0(1.0.1.2)0.09(1.0.1.12)0.091C1, amal/L1255(03.03.03)1020(08.5.01.20)10.00(06.6.3.01.03)0.01SCr, amal/L1450(01.3.0.21.47)1650(03.3.7.320.29)0.01BUN, amal/L1262(149.3.264.87)2755(141.8.371.69)1500(11.4.2.4.14)0.182ALB, g/L22.3.5.5.527.5.5.3.7.127.2.5.4.00.001Serum prealbumin, mg/L63.50(05.0.0.4)63.00(34.5.6.5.0)1.2.0.2.5.5.10.021Serum prealbumin, mg/L12.9.3.0.009.7.0.3.1.6.1)1.2.0.2.4.5.00.021Serum prealbumin, mg/L10.9.0.009.7.0.3.1.6.1)1.2.0.4.0.0.000.021Serum prealbumin, mg/L10.9.0.009.7.0.3.1.6.1)1.2.0.4.0.0.000.002Serum prealbumin, mg/L10.9.0.009.7.0.3.1.6.1)1.2.0.4.0.0.000.002Serum prealbumin, mg/L10.9.0.009.7.0.3.1.6.1)1.2.0.4.0.0.000.002Serum prealbumin, mg/L10.9.0.0.009.7.0.3.1.6.1)1.2.0.4.0.0.000.002Serum prealbumin, mg/L10.9.0.0.009.7.0.0.0.0.000.0020.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	Laboratory parameters				
Cl, mmol/L1028 (98,0, 00.0)1020 (98,5, 112.0)1030 (96,6, 104.0)0.19SCr, µmol/L14850 (91.3, 21.473)1680 (73.85, 190.10)11355 (72.0, 29.73)0.01BUN/SCr162.3 (149.83, 264.87)20.81 (13.02, 29.55)1500 (11.43, 24.14)0.18BUN, mmol/L26.3 ± 5.5527.5 ± 3.717.52 ± 5.400.90Serum prealbumin, mg/L68.55 (10.64)8.40 (84.58, 65.5)8.12 (63.64, 118.38)0.94PCT, ng/mL19.2 ± 1.1 ±18.47 ± 9.412.13 ± 1.1.340.87CR, mg/L0.41 ± 9.2036.40 ± 86.510.40 (21.0 s3)0.76Uyn 10 ⁷ /L0.40 (20.0 s3)0.45 (14.22)32.00 (21.0 c3.0)0.76Nop, ng/ML32.0 (45.57)0.53 (14.22)32.00 (21.0 c3.0)0.76Nop, ng/ML32.0 (45.57)0.53 (15.20, 0.62)0.20 (12.0 c3.0)0.07Delimin0.31 (20.53)0.53 (12.00 (20.03)0.020.07Nop, ng/ML32.0 (45.57)0.53 (15.20, 0.62)0.20 (10.20, 53.10)0.07Delimin12.0 (30.000.20 (30.000.070.07Delimin12.0 (30.001.50 (20.000.070.07Delimin12.0 (20.001.61 (20.000.070.07Delimin12.0 (20.001.62 (20.001.62 (20.000.07Delimin12.0 (20.001.62 (20.001.62 (20.000.07Delimin12.0 (20.001.62 (20.001.62 (20.000.02Delimin12.0 (20.001.62 (20.001.62 (20.00Delimin </td <td>K⁺, mmol/L</td> <td>3.89 ± 0.62</td> <td>3.92 ± 0.83</td> <td>4.17 ± 0.74</td> <td>0.078</td>	K ⁺ , mmol/L	3.89 ± 0.62	3.92 ± 0.83	4.17 ± 0.74	0.078
Kr, µmol/LH830 (91.02, 214.73)H680 (73.85, 190.10)H355 (72.02, 297.34)0.534BUN/SCr16.26 (14.9.83, 26.4.87)67.56 (14.18, 37.1.60)150 (11.43, 24.14)0.151BUN, mon/L62.3 ± 5.550.51 (13.02, 29.55)150 (11.43, 24.14)0.361ALB, g/L63.55 (50.01.50)63.40 (38.45, 86.55)81.20 (63.68, 118.38)0.042Serum prealbumin, mg/L63.55 (50.01.50)95.73 (18.31.61)14.58 (24.03.40.00)0.94PCT, ng/nL12.9 (3.40, 50.00)95.73 (18.31.61)14.58 (24.03.40.00)0.94VBC, 10 ⁶ /L19.12 ± 11.1218.47 ± 9.410.31 ± 11.340.387CRP, mg/L0.41 (49.20.02)0.64 ± 86.190.60 (21.0.65)0.63Lym, 10 ⁶ /L0.43 (20.0.53)0.53 (0.20, 6.62)0.20 (21.0.62)0.76My, ng/mL0.27 (35.03, 16.20)0.20 (19.10.62)0.76Boly temperature max, °C13.15 (77.40, 86.00)12.10.53, 142.010.76Dirimin12.10.350.21.05.310.010.01Dirimin12.10.350.21.05.010.10.10.1010.20Boly temperature max, °C15.77.03.80.0112.80.020.76CRT16.72.5316.80.2012.81.930.01Dirimin16.72.5316.82.9316.33.30.010.02CRT16.92.5216.81.9316.33.930.02CRT16.92.5216.22.54.0216.33.13.010.10GSC area16.92.5216.24.14.0316.42.14.0316.42GSC Area16.	Ca ²⁺ , mmol/L	1.08 (1.04, 1.17)	1.08 (1.02, 1.20)	1.09 (1.06, 1.12)	0.895
NUNSCR26.23 (49.83, 26.43)26.75 (94.18, 37.69)18.0 (133.73, 28.02)0.01BUN/SCR5.90 (11.5, 25.89)0.81 (13.0, 29.59)15.00 (11.43, 24.14)0.85ALB, g/L6.23 ± 5.550.53 (0.450)6.340 (84.5, 86.55)81.20 (63.68, 11.8.38)0.42Serum preabumin, mg/L12.9 (3.40, 50.00)9.87 (3.15, 31.61)14.58 (2.40, 34.00)0.94NED, 10 ⁶ /L12.9 (3.40, 50.00)9.87 (3.15, 31.61)14.58 (2.40, 34.00)0.94VBC, 10 ⁶ /L19.12 ± 11.1218.47 ± 9.410.31 ± 11.340.87CRF, mg/L0.34 (0.20, 0.53)0.64 9± 86.190.40 (0.21, 0.65)0.76Lym, 10 ⁶ /L0.34 (0.20, 0.53)0.35 (0.20, 0.62)0.40 (0.21, 0.65)0.76NT-proBNP, ng/L26.76 (0.66, 80.20)12.01 (63.5, 142.21)32.00 (9.21, 0.62)0.72Body temperature max, °C3.15 (07.40, 38.60)7.50 (75.0, 38.40)3.75 (72.0, 38.10)0.01Dirinum12.19.350.61 (3.51, 422.1)32.00 (9.21, 0.62)0.02Dirinum12.19.350.12 (3.51, 422.1)32.00 (9.21, 0.62)0.02Dirinum12.19.350.12 (3.51, 422.1)10.10 (3.51, 422.1)0.02Dirinum12.19.3514.82 (9.30)10.10 (3.30)0.02CRT45.75, 0.05, 0.0114.82 (9.30)10.230.02Dirinum50.75, 0.05, 0.0113.13.980.010.02CRT50.05, 0.0150.01, 0.00, 0.0050.30, 0.07, 0.010.02CRT60.45, 0.02, 0.0214.24, 4.04	Cl ⁻ , mmol/L	102.85 (98.03, 106.03)	103.20 (98.50, 112.05)	100.30 (96.63, 104.03)	0.019
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container></table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row></table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row></table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row></table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-container></table-row></table-container></table-row></table-container></table-row></table-row></table-row></table-container></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	SCr, µmol/L	148.50 (91.30, 214.73)	116.80 (73.85, 190.10)	113.55 (72.00, 297.38)	0.524
Alb. g/L 2.22 ± 5.57 2.7.52 ± 3.71 27.52 ± 3.71 27.52 ± 3.71 0.29 Serum prealbumin, mg/L 68.35 (0.55, 100.45) 63.40 (38.45, 86.55) 81.20 (63.68, 118.38) 0.042 PCT, ng/nL 11.29 (3.40, 50.00) 9.87 (3.18, 31.61) 14.58 (2.40, 34.00) 0.964 WBC, 10 ⁹ /L 19.12 ± 11.12 18.47 ± 9.41 21.31 ± 11.34 0.837 CRP, mg/L 19.14 ± 9.12 0.64.94 ± 66.19 16.42 ± 84.56 0.683 Lym, 10 ⁹ /L 0.34 (0.20, 0.53) 0.53 (0.20, 0.62) 0.40 (0.21, 0.63) 0.720 Myo, ng/L 0.34 (0.20, 0.53) 0.35 (0.20, 0.62) 0.40 (0.21, 0.63) 0.720 Myo, ng/L 29.73 (80.6 (0.20) 4221 (435, 14221) 320 (10, 0.33) 0.720 Myo, ng/L 29.73 (80.6 (0.20) 7.50 (37.20, 38.10) 0.017 Delrivemontare max, "C 315 (3.74.0, 38.60) 37.80 (37.50, 38.40) 37.50 (37.20, 38.10) 0.017 Interventions 1 12.93.70 34 (82.93) 27 (50.00, 0.30) 6.053 CRR do Sore 6.04 (50.10.00) 50 (3.00, 0.00) <	BUN/SCr	216.23 (149.83, 264.87)	267.56 (194.18, 371.69)	185.06 (133.73, 250.25)	0.001
TotalAutomaticalAutomaticalAutomaticalAutomaticalAutomaticalBern, mendulumin, mg/L6435 (50,51,00,45)6,40 (40,40,40,40,40,40,40,40,40,40,40,40,40,4	BUN, mmol/L	18.90 (11.15, 25.88)	20.81 (13.20, 29.55)	15.00 (11.43, 24.14)	0.185
PCT, rot I.129 (Ab, 50.00) 9.87 (3.18, 31.61) 14.58 (2.40, 34.00) 0.964 WBC, 10 ³ /L 19.12 ± 11.12 18.47 ± 9.41 21.31 ± 11.34 0.387 CRP, mg/L 19.14 ± 92.02 206.49 ± 86.19 16.64 2 ± 84.56 0.083 Lym, 10 ⁹ /L 0.34 (0.20, 0.53) 0.35 (0.20, 0.62) 0.40 (0.21, 0.63) 0.765 NT-proBNP, ng/L 257 (3606, 8020) 4221 (635, 14221) 3220 (912, 10625) 0.008 Myo, ng/mI 329 (146, 575) 706 (316, 1952) 259 (120, 030) 0.007 Body temperature max, "C 31.5 (37.40, 38.60) 37.80 (75.0, 38.40) 37.50 (72.0, 38.10) 0.017 Delirium 12 (9.35) 9 (21.95) 8 (14.81) 0.657 Delirium 4 (36.71) 8 (43.90) 8 (3.33) 0.02 CRRT 40.80,10.001 500 (30,0.600) 6.03 (30,9.75) 0.019 APACHE II score 17.94 5.52 17.24 6.40 16.33 ± 8.30 0.01 QSFA score 10.31 ± 3.98 10.64 ± 4.08 9.48 ± 5.41 0.444 Bradgenic	ALB, g/L	26.23 ± 5.55	27.55 ± 3.71	27.52 ± 5.40	0.290
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container></table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-container><table-container></table-container></table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row><table-row><table-row><table-container><table-row><table-container></table-container></table-row><table-row></table-row><table-row><table-row><table-container><table-row></table-row><table-row></table-row><table-row><table-row><table-container><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-container><table-row></table-row></table-container></table-container></table-row></table-row></table-container></table-row></table-row></table-container></table-row></table-row></table-row></table-container></table-row></table-row></table-row></table-container></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	Serum prealbumin, mg/L	68.35 (50.55, 100.45)	63.40 (38.45, 86.55)	81.20 (63.68, 118.38)	0.042
CR, mg/L19.49 ±9.2026.49 ±8.61916.42 ±8.4500.88Lym, 10 ⁴ /L3.40 ±0.0333.50 ±0.0623.60 ±0.0133.60 ±0.013NT-proBN, ng/L26.30 ±0.02321.60 ±0.0133.20 ±0.0133.20 ±0.013Myo, ng/mL29.01 ±0.01329.010 ±0.0133.50 ±0.0133.50 ±0.013Bolt therman, CO3.51 ±0.0133.60 ±0.0133.50 ±0.0133.50 ±0.013Delinium10.93 ±0.0133.60 ±0.0133.50 ±0.0133.50 ±0.013Delinium10.93 ±0.0133.60 ±0.0133.60 ±0.0133.60 ±0.013Delinium4.62 ±0.0133.61 ±0.0133.60 ±0.0133.60 ±0.013Delinium4.62 ±0.0133.61 ±0.0133.60 ±0.0133.60 ±0.013Delinium4.62 ±0.0133.61 ±0.0133.61 ±0.0133.61 ±0.013Delinium4.61 ±0.0133.61 ±0.0133.61 ±0.0133.61 ±0.013 <t< td=""><td>PCT, ng/mL</td><td>11.29 (3.40, 50.00)</td><td>9.87 (3.18, 31.61)</td><td>14.58 (2.40, 34.00)</td><td>0.964</td></t<>	PCT, ng/mL	11.29 (3.40, 50.00)	9.87 (3.18, 31.61)	14.58 (2.40, 34.00)	0.964
Number040,020,033035(020,062)040(021,063)076NT-proBNP,ng/L2673(806,802)4221(635,14221)320(912,10625)0.008Myo,ng/mL329(146,75)76(316,1952)59(120,63)0.008Body temperature max, °C3515(740,38.60)750(750,38.40)750(720,38.10)0.017Delirium12 (19.35)9(19.5)8(14.81)0.657Interventions512512500(00,000)600CRT45(72,5)4(82,93)750,000,0000.02CRT4(30,10,00)16(3,00,07)0.02507CRS core600(50,01,00)500(3,00,60)630(3,00,975)0.109APACHE II score11,2912,24.40638,8.300.01QSFA score10,31,3.9816,44.08948,5.410.44Store500(3,00,01)607,80.0010,920.49SPA score10,31,3.9816,45.0010,920.49Pathegeric500,30,4010,81,3010,920.49CFA score10,1224,8310,85,200.19Graderia71,2924,8310,85,200.19Graderia11,2924,8310,85,200.103Graderia16,60,0016,70,0010,95,100.03Graderia16,0020,00,0010,95,100.03Graderia16,60,0016,70,0010,95,100.03Graderia16,60,0016,70,0010,95,100.03Graderia16,60,0016,90,0010,90,00	WBC, 10 ⁹ /L	19.12 ± 11.12	18.47 ± 9.41	21.31 ± 11.34	0.387
NT-proBNP, ng/L 2673 (806, 8020) 421 (835, 14221) 320 (912, 10625) 0.720 Myo, ng/mL 329 (146, 575) 706 (316, 1952) 259 (120, 630) 0.008 Body temperature max, °C 351 (37.40, 38.60) 37.80 (37.50, 38.40) 37.50 (37.20, 38.10) 0.017 Delirium 12 (19.35) 9 (21.95) 8 (14.81) 0.657 Interventions 14 (27.58) 14 (82.93) 27 (50.00) 0.002 CRRT 43 (87.10) 18 (43.90) 13 (33.33) 0.573 CRStores 400 (5.00, 10.00) 500 (3.00, 6.00) 650 (3.00, 9.75) 0.019 APACHE II score 14.2 1.72 ± 6.40 6.38 ± 8.30 0.019 SOFA score 10.31 ± 3.98 10.64 ± 4.08 9.48 ± 5.41 0.44 SIRS 6.09.32 6.67.302 6.92.502 0.498 Pathogenic 1.64 ± 4.08 9.48 ± 5.41 0.44 SIRS 6.09.32 6.67.302 6.92.502 0.498 Pathogenic 1.292 0.126	CRP, mg/L	191.49 ± 92.02	206.49 ± 86.19	166.42 ± 84.56	0.083
Myo, ng/mL 329 (146, 575) 706 (316, 1952) 259 (120, 630) 0.008 Body temperature max, °C 38.15 (37.40, 38.60) 37.80 (37.50, 38.40) 37.50 (37.20, 38.10) 0.017 Delirium 12 (19.35) 9 (21.95) 8 (14.81) 0.657 Interventions 50 7.60 (30.00) 0.002 CRR 45 (72.58) 34 (82.93) 2 (50.00) 0.002 CInical scores 44 (38.71) 18 (43.90) 18 (33.33) 0.573 CIrical scores 500 (30.0, 60.00) 650 (30.0, 9.75) 0.109 APACHE II score 17.49 ± 5.52 17.2 ± 6.40 16.38 ± 8.30 0.001 qSOFA score 10.31 ± 3.98 10.64 ± 4.08 9.48 ± 5.41 0.444 SIRS 6 (00.32) 6 (87.80) 10 (2.59) 0.498 Pathogenic 1.52 1.52 1.52 G [*] bacteria 1 (1.29) 2 (4.88) 10 (18.52) 0.126 G [*] bacteria 1 (50.00) 2 (7.30) 10.418.10 0.	Lym, 10 ⁹ /L	0.34 (0.20, 0.53)	0.35 (0.20, 0.62)	0.40 (0.21, 0.63)	0.765
Body temperature max, °C 38.15 (37.40, 38.60) 37.80 (37.50, 38.40) 37.50 (37.20, 38.10) 0.017 Delirium 12 (19.35) 9 (21.95) 8 (14.81) 0.657 Interventions 57 (27.00, 38.40) 8 (14.81) 0.002 CRRT 45 (72.58) 34 (82.93) 27 (50.00, 0.002 0.002 CRRT 45 (37.10, 38.40) 18 (33.3) 0.573 Clinical scores 50 (30.0, 6.00) 6.00 (30.0, 9.75) 0.109 APACHE II score 60 (50.0, 10.00) 5.00 (3.00, 6.00) 6.50 (3.00, 9.75) 0.109 qSOFA score 10.49 ± 5.52 1.72 ± 6.40 16.38 ± 8.30 0.001 qSOFA score 10.31 ± 3.98 10.64 ± 4.08 9.48 ± 5.41 0.44 SIRS 6 (0.02) 36 (87.80) 50 (25.90) 0.498 Pathogenic - - - - G* bacteria 7 (11.29) 2 (4.88) 10 (18.52) 0.126 G* bacteria 1 (50.00) 2 (7.37) 10 (35.19) 0.003 Fungi 5 (8.	NT-proBNP, ng/L	2673 (806, 8020)	4221 (635, 14221)	3220 (912, 10625)	0.720
Defining12 (193)9 (219)8 (143)0.637Interventions5 (253)5 (253)0.02MV4 (253)14 (253)1020.02CRT2 (303)13 (303)13 (303)0.03Clinical cores5 (303,05,00)5 (303,075)0.01CAScore6 (050,010)5 (030,070)6 (030,010)0.01APACHE I score14 (353)102 (353,020)0.01APACHE I score10,20,000102 (353,000)0.02APACHE Score10,20,000104 (353,000)0.02APACHE Score10,20,000102,0000.02APACHE Score10,20,000102,0000.02APACHE Score10,20,00010,0000.02APACHE Score10,00010,00010,000APACHE Score10,00010,00010,000 <td>Myo, ng/mL</td> <td>329 (146, 575)</td> <td>706 (316, 1952)</td> <td>259 (120, 630)</td> <td>0.008</td>	Myo, ng/mL	329 (146, 575)	706 (316, 1952)	259 (120, 630)	0.008
Interventions Product of the second sec	Body temperature max, °C	38.15 (37.40, 38.60)	37.80 (37.50, 38.40)	37.50 (37.20, 38.10)	0.017
MV45(72.58)34(82.93)27(50.01)0.002CRT24(87.71)16(43.02)16(33.31)0.573Clinicat cores50(30.01,02)50(30.02,02)10.91GCS core60(50.01,02)50(30.02,02)60(30.02,02)APACHE I score17.49.55221.72.6.406.38.8.300.01GOFA score10.1221.72.6.4016.38.8.300.01GOFA score10.1221.72.6.4016.92.101.29GOFA score10.13.9.3010.64.4.809.48.5.1.40.44GNS6.03.2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	Delirium	12 (19.35)	9 (21.95)	8 (14.81)	0.657
CRRT 24 (38.71) 18 (43.90) 18 (33.33) 0.573 Clinical scores 500 (3.00, 6.00) 6.50 (3.00, 9.75) 0.109 GCS score 6.00 (5.00, 10.00) 5.00 (3.00, 6.00) 6.50 (3.00, 9.75) 0.001 APACHE II score 17.49 ± 5.52 21.72 ± 6.40 16.38 ± 8.30 0.001 qSOFA score 1 (1, 2) 2 (1, 2) 2 (1, 2) 0.239 SOFA score 10.31 ± 3.98 16.64 ± 4.08 9.48 ± 5.41 0.444 SIRS 56 (90.32) 3 (87.80) 50 (92.59) 0.498 Pathogenic	Interventions				
Clinical scores 6.00 (5.00, 10.00) 5.00 (3.00, 6.00) 6.50 (3.00, 9.75) 0.109 APACHE II score 17.49 ± 5.52 21.72 ± 6.40 16.38 ± 8.30 0.001 qSOFA score 1 (1, 2) 2 (1, 2) 0.239 SOFA score 10.31 ± 3.98 10.64 ± 4.08 9.48 ± 5.41 0.444 SIRS 6 (9.0.32) 3 (87.80) 5 (9.2.59) 0.498 Pathogenic - - - - - G ⁺ bacteria 7 (12.9) 2 (4.80) 10 (18.52) 0.126 G ⁺ bacteria 3 (50.00) 2 (9.07.3) 19 (35.19) 0.030 Fungi 5 (8.60) 3 (7.32) 8 (4.81) 0.380 G ⁺ and G ⁺ bacteria, n (%) 4 (45) 12 (4.9) 2 (3.70) 5.94	MV	45 (72.58)	34 (82.93)	27 (50.00)	0.002
GCS score 6.00 (5.00, 10.00) 5.00 (3.00, 6.00) 6.00 (3.00, 9.70) 0.109 APACHE II score 1749 5.52 1.72 ± 6.40 16.38 ± 8.30 0.001 qSOFA score 10, 12, 12 2.1, 22 1.2, 22 0.23 SOFA score 10, 12, 12 1.64 ± 4.08 9.48 ± 5.41 0.44 SNS 5.09, 02, 02 3.67, 80, 02 9.69, 80, 02 0.49 Pathogenic 5.00, 02, 02 3.67, 80, 02 0.42 0.43 G ¹ bacteria 71.29, 02 24, 80, 02 1.03, 80, 02 0.29 G ¹ bacteria 3.16, 00, 02 3.67, 02 3.03, 02 3.03 Fungi 5.60, 02 3.67, 02 3.62, 02 3.63 G ¹ can d ¹ bacteria, n(%) 5.60, 02 3.62, 02 3.63	CRRT	24 (38.71)	18 (43.90)	18 (33.33)	0.573
APACHE II score17.49 ± 5.5221.72 ± 6.4016.38 ± 8.300.001qSOFA score1 (1, 2)2 (1, 2)2 (1, 2)0.239SOFA score10.31 ± 3.9810.64 ± 4.089.48 ± 5.410.444SIRS56 (90.32)36 (87.80)50 (92.59)0.498Pathogenic55510.126G* bacteria7 (11.29)2 (4.88)10 (18.52)0.126G* bacteria31 (50.00)29 (70.73)19 (35.19)0.003Fungi5 (8.66)3 (7.32)8 (14.81)0.380G* and G* bacteria, n (%)4 (645)1 (2.44)2 (3.70)0.594	Clinical scores				
qSOFA score1(1,2)2(1,2)2(1,2)0.239SOFA score10.31 ± 3.9810.64 ± 4.089.48 ± 5.410.44SIRS5(90.32)3(87.80)5(92.59)0.498Pathogenic55551.26G* bacteria7(1.29)2(4.88)10(18.52)0.126G* bacteria15(500)29(70.73)19(35.19)0.003Fungi5(8.06)3(7.32)8(14.81)0.380G* and G* bacteria, n (%)164.5112.44)2(3.70)0.594	GCS score	6.00 (5.00, 10.00)	5.00 (3.00, 6.00)	6.50 (3.00, 9.75)	0.109
SOFA score 10.31 ± 3.98 10.64 ± 4.08 9.48 ± 5.41 0.444 SIRS 56 (90.32) 36 (87.80) 50 (92.59) 0.498 Pathogenic 5 5 9.48 ± 5.41 0.444 G ⁺ bacteria 7 (11.29) 2 (4.88) 10 (18.52) 0.126 G ⁺ bacteria 31 (50.00) 2 9 (70.73) 19 (35.19) 0.003 Fungi 5 (8.06) 3 (7.32) 8 (14.81) 0.380 G ⁺ and G ⁻ bacteria, n (%) 4 (6.45) 1 (2.44) 2 (3.70) 0.594	APACHE II score	17.49 ± 5.52	21.72 ± 6.40	16.38 ± 8.30	0.001
SIRS 56 (90.32) 36 (87.80) 50 (92.59) 0.498 Pathogenic G ⁺ bacteria 7 (11.29) 2 (4.88) 10 (18.52) 0.126 G ⁺ bacteria 11 (50.00) 2 9 (70.73) 19 (35.19) 0.003 Fungi 5 (8.06) 3 (7.32) 8 (14.81) 0.380 G ⁺ and G ⁺ bacteria, n (%) 4 (645) 1 (2.44) 2 (3.70) 0.594	qSOFA score	1 (1, 2)	2 (1, 2)	2 (1, 2)	0.239
Pathogenic 7 (11.29) 2 (4.88) 10 (18.52) 0.126 G ⁺ bacteria 31 (50.00) 29 (70.73) 19 (35.19) 0.003 Fungi 5 (8.06) 3 (7.32) 8 (14.81) 0.380 G ⁺ and G ⁻ bacteria, n (%) 4 (6.45) 1 (2.44) 2 (3.70) 0.594	SOFA score	10.31 ± 3.98	10.64 ± 4.08	9.48 ± 5.41	0.444
G ⁺ bacteria 7 (11.29) 2 (4.88) 10 (18.52) 0.126 G ⁻ bacteria 31 (50.00) 29 (70.73) 19 (35.19) 0.003 Fungi 5 (8.06) 3 (7.32) 8 (14.81) 0.380 G ⁺ and G ⁻ bacteria, n (%) 4 (6.45) 1 (2.44) 2 (3.70) 0.594	SIRS	56 (90.32)	36 (87.80)	50 (92.59)	0.498
G ⁻ bacteria 31 (50.00) 29 (70.73) 19 (35.19) 0.003 Fungi 5 (8.06) 3 (7.32) 8 (14.81) 0.380 G ⁺ and G ⁻ bacteria, n (%) 4 (6.45) 1 (2.44) 2 (3.70) 0.594	Pathogenic				
Fungi 5 (8.06) 3 (7.32) 8 (14.81) 0.380 G ⁺ and G ⁻ bacteria, n (%) 4 (6.45) 1 (2.44) 2 (3.70) 0.594	G ⁺ bacteria	7 (11.29)	2 (4.88)	10 (18.52)	0.126
G^+ and G^- bacteria, n (%) 4 (6.45) 1 (2.44) 2 (3.70) 0.594	G ⁻ bacteria	31 (50.00)	29 (70.73)	19 (35.19)	0.003
	Fungi	5 (8.06)	3 (7.32)	8 (14.81)	0.380
G ⁺ bacteria and fungi, n (%) 1 (1.61) 0 (0.00) 1 (1.85) 0.695	G^{+} and G^{-} bacteria, n (%)	4 (6.45)	1 (2.44)	2 (3.70)	0.594
	G^{+} bacteria and fungi, n (%)	1 (1.61)	0 (0.00)	1 (1.85)	0.695



G ⁻ bacteria and fungi	3 (4.84)	1 (2.44)	2 (3.70)	0.823
Time				
ICU LOS, days	16.50 (8.75, 26.75)	12.00 (5.00, 25.50)	5.00 (2.00, 12.00)	< 0.001
LOS outside the ICU, days	0.00 (0.00, 9.00)	0.00 (0.00, 7.00)	2.00 (0.00, 11.25)	0.155
Died within 14 days	22 (35.48)	22 (53.66)	20 (37.04)	0.146

IAH: ICU-acquired hypernatremia; ICU: Intensive care unit; CHD: Coronary heart disease; SAE: Sepsis-associated encephalopathy; SCr: Serum creatinine; BUN/SCr: Urea-to-creatinine ratio; BUN: Blood urea nitrogen; ALB: Serum albumin; PCT: Procalcitonin; WBC: White blood cell counts; CRP: C-reactive protein; Lym: Lymphocytes; NT-proBNP: N-terminal pro-B-type natriuretic peptide; Myo: Myoglobin; MV: Mechanical ventilation; CRRT: Continuous renal replacement therapy; GCS: Glasgow coma scale; APACHE II: Acute physiology and chronic health evaluation II; qSOFA: Quick sequential organ failure assessment; SOFA: Sequential organ failure assessment; SIRS: Systemic inflammatory response syndrome; LOS: Length of stay.




Figure 1 Flow chart of patients involved in this study. ICU: Intensive care unit; IAH: Intensive care unit-acquired hypernatremia.

However, in RR patients, the ratio was as high as 64.29%. In addition, the proportion of IAH varied among the different groups, with 55.81% in PICS, 55.00% in CCI and only 26.19% in RR (Figure 2A and B). The bar chart showed that 53.23% of patients with IAH developed CCI and only 17.74% of patients with RR. The reverse was true for patients with normonatremia (CCI: 16.67% vs RR: 50.00%). The data for patients with non-IAH were very similar to those of patients with IAH, with no statistically significant difference between the two groups. However, the statistical significance in both groups was greater than that observed in the normonatremia group (Figure 2B). Additionally, an analysis based on PICS criteria revealed a trend consistent with that seen in CCI (Figure 2A and B). These findings suggest a significant association between elevated serum sodium levels and both PICS and CCI, particularly in patients with IAH, whereas RR was significantly associated with normonatremia. Hence, the state of elevated sodium can predict poor clinical trajectories with septic shock patients.

Risk factors for IAH in patients with septic shock

The univariate logistic regression analysis demonstrated that IAH had an apparent association with kidney insufficiency [odds ratio (OR) = 0.22; 95% CI: 0.06-0.86; P = 0.029], the total urine volume in the preceding three days (OR = 1.10; 95% CI: 1.04-1.17; P = 0.002), the sodium content of enteral nutrition (EN) = 500mg (OR = 3.18; 95% CI: 1.36-7.45; P = 0.008), the sodium content of EN = 670mg (OR = 5.52; 95% CI: 1.74-17.49; P = 0.004), and diuretic (OR = 2.44; 95% CI: 1.14-5.21; P = 0.021) (Table 2). These significant characteristics in the univariate analyses were entered into multivariate models. The results showed that total urine volume in the preceding three days (OR = 1.09; 95% CI: 1.02-1.17; P = 0.014), the sodium content of EN = 500mg (OR = 2.93; 95% CI: 1.13-7.60; P = 0.027) and the sodium content of EN = 670mg (OR = 6.19; 95% CI: 1.75-21.98; P = 0.005) were positively correlated independent risk factors for the development of IAH (Table 3).

Prediction for the occurrence of IAH

After identifying the independent risk factors, ROC analysis was used to calculate the AUC for each factor to better predict the occurrence of IAH. As shown in Figure 3 and Table 4, the urine output on the first day (AUC = 0.75, 95%CI: 0.60-0.90, *P* = 0.008), second day (AUC = 0.77, 95% CI: 0.63-0.91, *P* = 0.004), and third day (AUC = 0.78, 95% CI: 0.65-0.91,

WJCC | https://www.wjgnet.com

Shi MQ et al. Hypernatremia in patients with septic shock

Table 2 Univariate analysis for risk factors of intensive care unit-acquired hypernatremia in septic shock patients, n (%)/mean ± SD					
	IAH	Normonatremia	Univariate		
	(<i>n</i> = 62)	(<i>n</i> = 54)	OR (95%CI)	P value	
Diabetes mellitus	17 (27.42)	10 (18.52)	1.66 (0.69-4.03)	0.26	
Kidney insufficiency	3 (4.84)	10 (18.52)	0.22 (0.06-0.86)	0.029	
Body temperature max, °C	38.15 (37.40-38.60)	37.50 (37.20-38.10)	1.17 (0.85-1.60)	0.348	
Urine volume, ml					
$1^{st} + 2^{nd} + 3^{rd}$	5775.00 (2908.75-7512.50)	3730.00 (257.50, 5732.50)	1.10 (1.04-1.17)	0.002	
The sodium content of EN					
315 mg	13 (20.97)	7 (12.96)	1.78 (0.65-4.85)	0.259	
500 mg	26 (41.94)	10 (18.52)	3.18 (1.36-7.45)	0.008	
670 mg	19 (30.65)	4 (7.41)	5.52 (1.74-17.49)	0.004	
Diuretic	43 (69.35)	26 (48.15)	2.44 (1.14-5.21)	0.021	
Mannitol	8 (12.90)	4 (7.41)	1.85 (0.53-6.53)	0.338	
Glucocorticoids	37 (59.68)	27 (50.00)	1.48 (0.71-3.09)	0.296	
Blood glucose max, mmol/L	10.86 ± 3.62	9.73 ± 3.51	1.09 (0.98-1.22)	0.095	
CRP, mg/L	191.49 ± 92.02	166.42 ± 84.56	1.00 (1.00-1.01)	0.135	
Lym, 10 ⁹ /L	0.34 (0.20, 0.53)	0.39 (0.21, 0.62)	0.71 (0.31-1.62)	0.419	
Serum prealbumin, mg/L	68.35 (50.55, 100.45)	81.20 (63.68, 118.38)	0.99 (0.98-1.00)	0.073	
ALB, g/L	26.23 ± 5.55	27.52 ± 5.40	0.96 (0.89-1.03)	0.209	
BUN, mmol/L	18.90 (11.15, 25.88)	15.00 (11.43, 24.14)	1.00 (0.98-1.03)	0.833	
BUN/SCr	227.44 ± 117.94	198.05 ± 90.72	1.00 (1.00-1.01)	0.144	
APACHE II score	17.49 ± 5.52	16.38 ± 8.30	1.02 (0.97-1.08)	0.402	
SOFA score	10.31 ± 3.98	9.48 ± 5.41	1.04 (0.96-1.13)	0.356	
SIRS, <i>n</i> (%)	58 (93.55)	52 (96.30)	0.56 (0.10-3.17)	0.51	

IAH: ICU-acquired hypernatremia; ICU: Intensive care unit; OR: Odd ratio; EN: Enteral nutrition; CRP: C-reactive protein; Lym: Lymphocytes; ALB: Serum albumin; BUN: Blood urea nitrogen; BUN/SCr: Urea-to-creatinine ratio; APACHE II: Acute physiology and chronic health evaluation II; SOFA: Sequential organ failure assessment; SIRS: Systemic inflammatory response syndrome.

Table 3 Multivariate analysis for independent risk factors of intensive care unit-acquired hypernatremia in septic shock patients, n (%)				
	IAH	Normonatremia	Multivariate	Dyalua
	(<i>n</i> = 62)	(<i>n</i> = 54)	OR (95%CI)	P value
Kidney insufficiency	3 (4.84)	10 (18.52)	0.37 (0.08-1.67)	0.197
Urine volume, ml				
$1^{st} + 2^{nd} + 3^{rd}$	5775 (2908.75, 7512.5)	3730 (257.5, 5732.5)	1.09 (1.02-1.17)	0.014
The sodium content of EN				
500 mg	26 (41.94)	10 (18.52)	2.93 (1.13-7.60)	0.027
670 mg	19 (30.65)	4 (7.41)	6.19 (1.75-21.98)	0.005
Diuretics-	43 (69.35)	26 (48.15)	1.87 (0.78-4.47)	0.159

IAH: ICU-acquired hypernatremia; ICU: Intensive care unit; OR: Odd ratio; EN: Enteral nutrition.

Zaisbideng® WJCC | https://www.wjgnet.com

Table 4 Areas under the receiver operator curves presented of predicting intensive care unit-acquired hypernatremia				
Variable	AUC	95%CI	<i>P</i> value	
Urine volume $1^{st} + 2^{nd} + 3^{rd}$	0.80	0.68-0.92	0.001	
Urine volume 1 st	0.75	0.60-0.90	0.008	
Urine volume 2 nd	0.77	0.63-0.91	0.004	
Urine volume 3 rd	0.78	0.65-0.91	0.003	
The sodium content of EN	0.60	0.43-0.78	0.274	

AUC: Areas under the curve; ROC: Receiver operator curves; EN: Enteral nutrition.

P = 0.003) demonstrated good predictive potential for IAH. Notably, the total urine output over the first three days achieved an AUC of 0.80 (95%CI: 0.68–0.92, P = 0.001), indicating that the combined analysis of these three variables provided a stronger prediction for the occurrence of IAH compared to any single variable alone. However, the AUC for EN was less than 0.7 (AUC = 0.60, 95%CI: 0.43–0.78, P = 0.274), indicating lower predictive potential.

28-day in-hospital mortality with septic shock patients

The correlation between the 28-day in-hospital mortality of septic shock patients and serum sodium condition was expressed using Kaplan–Meier curve analysis (Figure 4). There was no significant statistical difference in 28-day inhospital mortality among the IAH, non-IAH and normonatremia groups (P = 0.255) (Figure 4A). Nevertheless, the different maximum serum sodium levels were significantly associated with 28-day mortality in patients (P = 0.035). Notably, the group with the lowest serum sodium concentration (145-150 mmol/L) exhibited a higher risk of death compared to other groups (Figure 4B). The duration of hypernatremia also showed a statistically significant effect on patient outcomes (P = 0.018), with patients experiencing hypernatremia for more than 20 days demonstrating the highest survival rate (Figure 4C). Further, the sodium correction rates had a significant impact on 28-day mortality (P = 0.030), with correction rates of 9-11 mmol/L per 24 hours associated with the best 28-day survival rate (Figure 4D). Subgroup analysis revealed that 28-day mortality was significantly higher in patients receiving CRRT for hypernatremia compared to those not treated with CRRT (Supplementary Figure 1). Supplementary Table 2 presented the 7-, 14-, and 28-day inhospital mortality rates for patients with septic shock.

DISCUSSION

In the present study, three significant data analyses were performed on hypernatremia in septic shock patients. Firstly, it was observed that elevated serum sodium status was highly correlated with poor clinical trajectory, especially IAH. Hence, independent risk factors for IAH were identified through multifactorial analysis, and their predictive utility was determined. Finally, the initial state, duration and correction rate of serum sodium can affect the short-term prognosis of septic shock patients.

Hypernatremia, especially IAH, was a significant factor leading to adverse clinical trajectory. A hypersaline state can lead to inappropriate activation of the immune system, driving macrophages to polarize into a pro-inflammatory phenotype[17]. Meanwhile, severe infection can disrupt the activity of the hypothalamic-pituitary-adrenal axis, increasing the body's demand for free water. This heightened need can result in significant free water deficiency, ultimately leading to hypernatremia[18]. This suggests that inflammation and elevated sodium levels have a bidirectional, cause-and-effect relationship. The present findings confirm a significant association between excessive sodium and PICS, which appears to form a self-sustaining vicious cycle. Among patients with PICS, 83.72% (36/43) exhibited hypernatremia, and 55.81% (24/43) had IAH (Figure 2A). Similarly, the incidence of PICS was higher in patients with hypernatremia (whether ICU-acquired or present at admission) compared to those with normonatremia (38.71% *vs* 29.27% *vs* 12.96%). This association mirrors the relationship between elevated serum sodium levels and CCI but is inversely related to the RR group (Figure 2B and C). Therefore, the interaction between hypernatremia, PICS, and CCI underscores the importance of monitoring and managing elevated serum sodium concentrations in septic shock patients.

In the ICU, the most common cause of hypernatremia is the loss of net water and the increase in sodium intake[19]. Both of these reasons are reflected in the present results. The total urine volume in the preceding three days and the sodium content of EN were identified as independent risk factors for IAH. In the ICU, most patients are supported by EN. Na⁺ is a key component of osmotic pressure in EN preparations, with osmolarity typically ranging from 490 to 790 mOsm/kg[20]. Research has shown that the higher the osmotic pressure difference between the gastrointestinal secretion and EN solution, the stronger the inhibition of the gastrointestinal tract on EN solution, which is manifested as excessive intake of sodium and insufficient intake of water[21,22]. At the same time, high osmotic pressure can also cause osmotic diarrhea, further causing high concentrated hypernatremia[23]. Based on the present data, when the sodium content of EN = 500mg, the risk of IAH increased 2.93 times (P = 0.027), and 6.19 times when it reached 670 mg (P = 0.005). Further, in patients with poor renal function or osmotic diseases, such as diabetes insipidus and osmotic diuresis, the balance of sodium and water is disrupted[24,25]. Na is reabsorbed by the renal tubules into the interstitial fluid, while the ascending




Figure 2 The relationship of persistent inflammation, chronic critical illness and rapid recovery for patients with septic shock between intensive care unit-acquired hypernatremia group, hypernatremia at admission group and normonatremia group. A: Patients with persistent inflammation; B: Patients with chronic critical illness; C: Patients with rapid recovery. ICU: Intensive care unit; PICS: Persistent inflammation, immunosuppression and catabolism syndrome; CCI: Chronic critical illness; RR: Rapid recovery.

limb of the loop of Henle actively secretes sodium into the interstitial space, which is impermeable to water[26]. As a result, Na is continuously pumped out resulting in an elevated blood sodium level[11]. Consequently, in patients with septic shock in ICU, it is recommended to choose EN formulations with low sodium content and to implement strict monitoring and control of total urine output during the first 3 days to help reduce the incidence of IAH.

Although previous studies have identified an optimal serum sodium cut-off value of 147.55 mmol/L in patients with critical nervous system conditions[27], the ideal serum sodium peak for patients with septic shock remains unclear. Notably, in the present study, septic shock patients exhibited the highest 28-day mortality (57.89%) when serum sodium levels ranged between 145 and 150 mmol/L, whereas the lowest 28-day mortality (12.50%) was observed when sodium levels were between 160 and 165 mmol/L. Based on these findings, maintaining serum sodium levels between 160 and 165 mmol/L. Based on these findings, maintaining serum sodium levels between sodium levels shock may offer a more favorable short-term prognosis compared to mild or severe sodium elevations. From a pathophysiological perspective, this differs from patients with sepsis or nervous system dysfunction.




Figure 3 The receiver-operating characteristic analysis of independent risk factors for intensive care unit-acquired hypernatremia. ROC: Receiver-operating characteristic. EN: Enteral nutrition.




Figure 4 Kaplan-Meier survival curves stratified by serum sodium for septic shock patients. A: Patients stratified by different types of serum sodium; B: Patients stratified by maximum serum sodium; C: Patients stratified by duration of hypernatremia; D: Patients stratified by sodium reduction rate.

In septic shock, a moderate increase in serum sodium can raise the osmotic pressure and tension of extracellular fluid, which may help reduce diffuse cerebral edema caused by septic encephalopathy. Additionally, it could mitigate hypovolemic shock due to extensive plasma leakage[28–31]. Moreover, clinical recommendations suggest that in patients with rapid hypernatremia, a correction rate of 1 mEq/L/h is considered safe, while patients with chronic hypernatremia should be corrected at a rate of 0.5 mEq/L/h, with a maximum change of 8 to 10 mEq/L/24h[19]. The present study is consistent with this result. The rate of sodium reduction at 9 to 11 mmol/L/24 hours was associated with the lowest 28-day in-hospital mortality, especially compared with the rapid correction group (11 to 15 mmol/L and \geq 15 mmol/L/24 hours). In summary, the present authors speculate that moderately persistent high serum sodium status may mitigate the

progression of histiocytic edema and hypovolemia resulting from septic shock, thereby improving patient outcomes.

While the present study yielded encouraging results, there are potential limitations to consider. First, it was a singlecenter study with a relatively small sample size. Second, the complexity of septic shock introduces multiple factors that may confound the association between hypernatremia and mortality. Despite these limitations, the findings present valuable insights into the relationship between hypernatremia, PICS, as well as the clinical trajectories of CCI and RR in septic shock patients. Further, the data suggest that the initial sodium levels, duration of hypernatremia, and sodium correction rates can significantly influence the short-term prognosis of septic shock patients. Given the rarity and high mortality rate of this life-threatening condition, conducting large-scale clinical studies can be difficult. Therefore, a larger multi-center study with a higher number of cases is warranted to confirm these results.

CONCLUSION

In summary, elevated serum sodium, particularly IAH, was identified as one of the most important factors influencing CCI and PICS in septic shock patients. The urine volume over the previous three days and the sodium content in EN were found to be independent risk factors for IAH, with total urine volume in the prior three days being a strong predictor. Additionally, the prognosis of septic shock patients was significantly associated with maximum serum sodium levels, the duration of hypernatremia, and the rate of sodium correction. At present, there are no globally accepted guidelines for the management of hypernatremia in septic shock. These findings suggest that hypernatremia may serve as a critical predictive indicator for patient outcomes in septic shock, underscoring the need for careful monitoring and management of sodium levels in these patients.

FOOTNOTES

Author contributions: Shi MQ, Wang X contributed to data curation, formal analysis, visualization; Wang Y, Ji FH contributed to conceptualization; Zhou H, Peng K, Wang J contributed to writing-original draft; Chen J, Fan CL writing-review and editing.

Supported by The National Natural Science Foundation of China, No. 82072130; Key Medical Research Projects in Jiangsu Province, No. ZD2022021; and Suzhou Clinical Medical Center for Anesthesiology, No. Szlcyxzxj202102.

Institutional review board statement: The study was conducted in accordance with the declaration of Helsinki. The First Affiliated Hospital of Soochow University's Institutional Review Board approved this study (approval number: 2023.228).

Informed consent statement: Written informed consent from the patients was not required to participate in this study in accordance with the national legislation and the institutional requirements.

Conflict-of-interest statement: The author(s) declare no conflict of interest relevant to the preparation of this manuscript.

Data sharing statement: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

ORCID number: Mai-Qing Shi 0009-0005-8042-6099; Yang Wang 0009-0006-3238-7352.

S-Editor: Liu H L-Editor: A P-Editor: Zhang XD

REFERENCES

- Fernando SM, Rochwerg B, Seely AJE. Clinical implications of the Third International Consensus Definitions for Sepsis and Septic Shock 1 (Sepsis-3). CMAJ 2018; 190: E1058-E1059 [PMID: 30201611 DOI: 10.1503/cmaj.170149]
- 2 Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395: 200-211 [PMID: 31954465 DOI: 10.1016/S0140-6736(19)32989-7]
- Bauer M, Groesdonk HV, Preissing F, Dickmann P, Vogelmann T, Gerlach H. [Mortality in sepsis and septic shock in Germany. Results of a 3



WJCC https://www.wjgnet.com

systematic review and meta-analysis]. Anaesthesist 2021; 70: 673-680 [PMID: 33559687 DOI: 10.1007/s00101-021-00917-8]

- 4 Rosenthal MD, Vanzant EL, Moore FA. Chronic Critical Illness and PICS Nutritional Strategies. *J Clin Med* 2021; 10 [PMID: 34070395 DOI: 10.3390/jcm10112294]
- 5 Davoudi A, Corbett DB, Ozrazgat-Baslanti T, Bihorac A, Brakenridge SC, Manini TM, Rashidi P. Activity and Circadian Rhythm of Sepsis Patients in the Intensive Care Unit. *IEEE EMBS Int Conf Biomed Health Inform* 2018; 2018: 17-20 [PMID: 30411088 DOI: 10.1109/BHI.2018.8333359]
- 6 Hesselink L, Hoepelman RJ, Spijkerman R, de Groot MCH, van Wessem KJP, Koenderman L, Leenen LPH, Hietbrink F. Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) after Polytrauma: A Rare Syndrome with Major Consequences. J Clin Med 2020; 9 [PMID: 31936748 DOI: 10.3390/jcm9010191]
- 7 Rosenthal MD, Kamel AY, Rosenthal CM, Brakenridge S, Croft CA, Moore FA. Chronic Critical Illness: Application of What We Know. Nutr Clin Pract 2018; 33: 39-45 [PMID: 29323761 DOI: 10.1002/ncp.10024]
- Liamis G, Filippatos TD, Elisaf MS. Evaluation and treatment of hypernatremia: a practical guide for physicians. *Postgrad Med* 2016; 128: 299-306 [PMID: 26813151 DOI: 10.1080/00325481.2016.1147322]
- 9 Olsen MH, Møller M, Romano S, Andersson J, Mlodzinski E, Raines NH, Sherak R, Jeppesen AN. Association Between ICU-Acquired Hypernatremia and In-Hospital Mortality: Data From the Medical Information Mart for Intensive Care III and the Electronic ICU Collaborative Research Database. Crit Care Explor 2020; 2: e0304 [PMID: 33354677 DOI: 10.1097/CCE.00000000000304]
- 10 De Freitas G, Gudur A, Vela-Ortiz M, Jodelka J, Livert D, Krishnamurthy M. Where there is sodium there may be sepsis. J Community Hosp Intern Med Perspect 2019; 9: 296-299 [PMID: 31528275 DOI: 10.1080/20009666.2019.1634407]
- 11 Lindner G, Funk GC, Schwarz C, Kneidinger N, Kaider A, Schneeweiss B, Kramer L, Druml W. Hypernatremia in the critically ill is an independent risk factor for mortality. *Am J Kidney Dis* 2007; 50: 952-957 [PMID: 18037096 DOI: 10.1053/j.ajkd.2007.08.016]
- 12 Waite MD, Fuhrman SA, Badawi O, Zuckerman IH, Franey CS. Intensive care unit-acquired hypernatremia is an independent predictor of increased mortality and length of stay. J Crit Care 2013; 28: 405-412 [PMID: 23369520 DOI: 10.1016/j.jcrc.2012.11.013]
- 13 Quinn JW, Sewell K, Simmons DE. Recommendations for active correction of hypernatremia in volume-resuscitated shock or sepsis patients should be taken with a grain of salt: A systematic review. SAGE Open Med 2018; 6: 2050312118762043 [PMID: 29593868 DOI: 10.1177/2050312118762043]
- 14 Rugg C, Ströhle M, Treml B, Bachler M, Schmid S, Kreutziger J. ICU-Acquired Hypernatremia Is Associated with Persistent Inflammation, Immunosuppression and Catabolism Syndrome. J Clin Med 2020; 9 [PMID: 32962124 DOI: 10.3390/jcm9093017]
- 15 Cox MC, Brakenridge SC, Stortz JA, Hawkins RB, Darden DB, Ghita GL, Mohr AM, Moldawer LL, Efron PA, Moore FA. Abdominal sepsis patients have a high incidence of chronic critical illness with dismal long-term outcomes. *Am J Surg* 2020; 220: 1467-1474 [PMID: 32807383 DOI: 10.1016/j.amjsurg.2020.07.016]
- 16 Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. *J Trauma Acute Care Surg* 2012; 72: 1491-1501 [PMID: 22695412 DOI: 10.1097/TA.0b013e318256e000]
- 17 Wenstedt EF, Verberk SG, Kroon J, Neele AE, Baardman J, Claessen N, Pasaoglu ÖT, Rademaker E, Schrooten EM, Wouda RD, de Winther MP, Aten J, Vogt L, Van den Bossche J. Salt increases monocyte CCR2 expression and inflammatory responses in humans. *JCI Insight* 2019; 4 [PMID: 31672939 DOI: 10.1172/jci.insight.130508]
- 18 Flierl MA, Rittirsch D, Weckbach S, Huber-Lang M, Ipaktchi K, Ward PA, Stahel PF. Disturbances of the hypothalamic-pituitary-adrenal axis and plasma electrolytes during experimental sepsis. Ann Intensive Care 2011; 1: 53 [PMID: 22208725 DOI: 10.1186/2110-5820-1-53]
- 19 Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and hypernatremia. Am Fam Physician 2015; 91: 299-307 [PMID: 25822386]
- 20 Barrett JS, Shepherd SJ, Gibson PR. Strategies to manage gastrointestinal symptoms complicating enteral feeding. JPEN J Parenter Enteral Nutr 2009; 33: 21-26 [PMID: 19028933 DOI: 10.1177/0148607108325073]
- 21 Wesselink E, Koekkoek KWAC, Looijen M, van Blokland DA, Witkamp RF, van Zanten ARH. Associations of hyperosmolar medications administered *via* nasogastric or nasoduodenal tubes and feeding adequacy, food intolerance and gastrointestinal complications amongst critically ill patients: A retrospective study. *Clin Nutr ESPEN* 2018; 25: 78-86 [PMID: 29779822 DOI: 10.1016/j.clnesp.2018.04.001]
- **Tatsumi H**. Enteral tolerance in critically ill patients. *J Intensive Care* 2019; 7: 30 [PMID: 31086671 DOI: 10.1186/s40560-019-0378-0]
- 23 Xin Y, Tian M, Deng S, Li J, Yang M, Gao J, Pei X, Wang Y, Tan J, Zhao F, Gao Y, Gong Y. The Key Drivers of Brain Injury by Systemic Inflammatory Responses after Sepsis: Microglia and Neuroinflammation. *Mol Neurobiol* 2023; 60: 1369-1390 [PMID: 36445634 DOI: 10.1007/s12035-022-03148-z]
- 24 Natochin YV, Golosova DV. Vasopressin receptor subtypes and renal sodium transport. *Vitam Horm* 2020; 113: 239-258 [PMID: 32138950 DOI: 10.1016/bs.vh.2019.08.013]
- Halmos EP, Muir JG, Barrett JS, Deng M, Shepherd SJ, Gibson PR. Diarrhoea during enteral nutrition is predicted by the poorly absorbed short-chain carbohydrate (FODMAP) content of the formula. *Aliment Pharmacol Ther* 2010; **32**: 925-933 [PMID: 20670219 DOI: 10.1111/j.1365-2036.2010.04416.x]
- 26 Bernal A, Zafra MA, Simón MJ, Mahía J. Sodium Homeostasis, a Balance Necessary for Life. Nutrients 2023; 15 [PMID: 36678265 DOI: 10.3390/nu15020395]
- 27 Hu B, Han Q, Mengke N, He K, Zhang Y, Nie Z, Zeng H. Prognostic value of ICU-acquired hypernatremia in patients with neurological dysfunction. *Medicine (Baltimore)* 2016; 95: e3840 [PMID: 27583842 DOI: 10.1097/MD.00000000003840]
- 28 Broll M, John S. [Hypernatremia]. Med Klin Intensivmed Notfmed 2020; 115: 263-274 [PMID: 32179951 DOI: 10.1007/s00063-020-00667-2]
- 29 Sakamoto A, Hoshino T, Boku K, Hiraya D, Inoue Y. Fatal acute hypernatremia resulting from a massive intake of seasoning soy sauce. Acute Med Surg 2020; 7: e555 [PMID: 32832094 DOI: 10.1002/ams2.555]
- 30 Hahn RG, Patel V, Dull RO. Human glycocalyx shedding: Systematic review and critical appraisal. Acta Anaesthesiol Scand 2021; 65: 590-606 [PMID: 33595101 DOI: 10.1111/aas.13797]
- 31 Mutter CM, Smith T, Menze O, Zakharia M, Nguyen H. Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management. *Cureus* 2021; 13: e13523 [PMID: 33786230 DOI: 10.7759/cureus.13523]

Zaishidena® WJCC | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

